Clinical trial
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
NCT00382629 · Bayhill Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00382629 |
|---|---|
| Title | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis |
| Official title | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis |
| Lead sponsor | Bayhill Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsing Remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | BHT-3009 0.5 mg, BHT-3009 1.5 mg, Placebo |
| Enrollment | 252 |
| Start date | Feb 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Sep 29, 2006 |
| Last update posted | Feb 11, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: